Exposomic Contributions to ADRD Pathology and Resilience
Funding Amount
Not stated
Deadline
Forecast — dates not yet posted
Grant Type
Federal
Can we apply?
Check your organization against each line. Taken from the listing; confirm with the funder's guidelines.
Eligible organizations
- Public & Indian housing authorities
- School districts
- Tribal organizations
- Public colleges & universities
- City & township governments
- County governments
- State governments
- Small businesses
Geography
- Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
Not eligible / not funded
- Not eligible: However, NIH-defined clinical trials will not be supported under this program.
Overview
The National Institute of Neurological Disorders and Stroke (NINDS) is interested in supporting research projects that investigate how specific neural exposome factors contribute mechanistically to Alzheimer’s disease-related dementias (ADRD) pathology and resilience. For the purposes of this program, exposome factors of interest include, but are not limited to, environmental toxins, sleep and circadian rhythms, stress, and the real-world conditions that modulate them (e.g., light, noise, heat). Applications will be expected to propose research on the synergistic action between multiple exposome factors, and the composite effects of mixtures of exposome factors on neural mechanisms relevant to ADRD. Applicants are encouraged to focus on mechanistic pathways (e.g., microbiome–brain interactions, neuroimmune signaling, epigenetic modifications) that link exposures to ADRD risk, progression, and resilience. Applicants are further encouraged to consider studies that cover the lifespan, including work that investigates critical or sensitive periods of exposure or factors that may lead to neurological health disparities. Applicants may propose mechanistic, translational, and/or human subjects research, drawing on clinical data, human samples, and observational or interventional studies. However, NIH-defined clinical trials will not be supported under this program. Applications are not currently being solicited. Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. Investigative teams with expertise in exposomics and environmental neuroscience, community engagement, ADRD mechanisms, and non-medical factors that may lead to health disparities are encouraged to apply.
Details
- Agency: National Institutes of Health
- Department: Department of Health and Human Services
- Opportunity #: RFA-NS-26-031
- Instrument: grant
Eligibility
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
Focus Areas & Funding Uses
Fields of Work
- Alzheimer's
- Science research
- Health disparities
Categories
Browse similar grants by category
Related Grants
Open grants from this funder and similar programs
Optimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Adolescents Clinical Centers (U01 Clinical Trial Required)
National Institutes of Health
Amount
Up to $1M
Deadline
October 9, 2026
Optimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Adolescents Research Coordinating Center (U24 Clinical Trial Not Allowed)
National Institutes of Health
Amount
Varies
Deadline
October 9, 2026
Development and Testing of a Multi-use Frameworks Playbook for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U01 Clinical Trial Not Allowed)
National Institutes of Health
Amount
$650,000 total
Deadline
October 9, 2026
Addressing Methodological Challenges with Clinical Trials of Rapid-Acting Psychotropic Interventional Drugs (RAPIDs) (R01 Clinical Trial Required)
National Institutes of Health
Amount
$5,000,000 total
Deadline
October 11, 2026
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
National Institutes of Health
Amount
Varies
Deadline
October 14, 2026
Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01 Clinical Trial Not Allowed)
National Institutes of Health
Amount
Varies
Deadline
October 14, 2026
Ready to apply for Exposomic Contributions to ADRD Pathology and Resilience?
Grantable helps you assess fit, draft narratives, and track deadlines — so you can submit stronger applications, faster.
You found Exposomic Contributions to ADRD Pathology and Resilience. Now let's win it.